Global Companion Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Global Companion Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease, predict drug toxicities, off-target effects of treatment, and other adverse effects related to the drug. It is also used during clinical trials to guide treatment, which can improve therapy responses and treatment outcomes. Currently, there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths were recorded in 2016. While in Europe, 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle, which is expected to fuel the growth of the companion diagnostics market in coming years.
The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally, high adoption of companion diagnostics, growing demand for companion diagnostics, and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.
Market Analysis: The “Global Companion Diagnostics” market is estimated to witness a CAGR of 19.6% during the forecast period 2018–2024. The market is analyzed based on four segments – technology, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe, Asia Pacific, and Rest of the World.
Technology Analysis: The global companion diagnostics market, by technology, is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next-generation sequencing, and others. Polymerase chain reaction occupied the largest share in 2017, and next-generation sequencing is expected to grow at a high CAGR in the coming years.
Application Analysis: The global companion diagnostics market, by application, is segmented into cancer, infectious disease, and others. The cancer application is further segmented into colorectal cancer, breast cancer, lung cancer, melanoma, and others. In 2017, cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer, changing lifestyle, and growing
For instance, in February 2017, Roche announced the launch of Elecsys AMH Plus immunoassay, the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance, in June 2017, the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the Oncomine Dx Target test, which instantaneously evaluates 23 genes clinically related to NSCLC.
Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease, predict drug toxicities, off-target effects of treatment, and other adverse effects related to the drug. It is also used during clinical trials to guide treatment, which can improve therapy responses and treatment outcomes. Currently, there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths were recorded in 2016. While in Europe, 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle, which is expected to fuel the growth of the companion diagnostics market in coming years.
The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally, high adoption of companion diagnostics, growing demand for companion diagnostics, and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.
Market Analysis: The “Global Companion Diagnostics” market is estimated to witness a CAGR of 19.6% during the forecast period 2018–2024. The market is analyzed based on four segments – technology, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe, Asia Pacific, and Rest of the World.
Technology Analysis: The global companion diagnostics market, by technology, is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next-generation sequencing, and others. Polymerase chain reaction occupied the largest share in 2017, and next-generation sequencing is expected to grow at a high CAGR in the coming years.
Application Analysis: The global companion diagnostics market, by application, is segmented into cancer, infectious disease, and others. The cancer application is further segmented into colorectal cancer, breast cancer, lung cancer, melanoma, and others. In 2017, cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer, changing lifestyle, and growing
For instance, in February 2017, Roche announced the launch of Elecsys AMH Plus immunoassay, the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance, in June 2017, the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the Oncomine Dx Target test, which instantaneously evaluates 23 genes clinically related to NSCLC.
Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Importance of Companion diagnostics
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the companion diagnostics market
3.5 Related Markets
3.5.1 Personalized medicine
3.5.2 Genetic testing Market
3.5.3 Point-Of-Care Diagnostics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Companion Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of cancer across the globe
5.1.1.2 Rising adoption of companion diagnostics tests
5.1.1.3 Growing demand of personalized medicine
5.1.2 Opportunities
5.1.2.1 Emerging applications of companion diagnostics
5.1.2.2 Growing demand for next-generation sequencing
5.1.3 Restraints
5.1.3.1 Uncertain reimbursement scenario in developed and developing countries
5.1.3.2 Lack of professionals to perform the test
6 TECHNOLOGY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Polymerase Chain Reaction
6.3 In Situ Hybridization
6.4 Immunohistochemistry
6.5 Next-Generation Sequencing
6.6 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Cancer
7.2.1 Lung cancer
7.2.2 Breast cancer
7.2.3 Colorectal cancer
7.2.4 Melanoma
7.2.5 Others
7.3 Infectious disease
7.4 Others
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Pharma and biopharma companies
8.3 Reference Laboratories
8.4 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 F.Hoffmann-La Roche Ltd
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 Qiagen N.V.
11.2.1 Overview
11.2.2 Geographic Presence
11.2.3 Business Focus
11.2.4 SWOT Analysis
11.2.5 Business Strategies
11.3 Abbott Laboratories
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Myriad Genetics Inc.
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Business Focus
11.4.4 SWOT Analysis
11.4.5 Business Strategy
11.5 Agilent Technologies Inc.
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 COMPANIES TO WATCH FOR
12.1 BioMerieux S.A.
12.1.1 Overview
12.1.2 BioMerieux S.A.: Recent Developments
12.2 Danaher Corporation (Leica Microsystems AG)
12.2.1 Overview
12.2.2 Danaher Corporation: Recent Developments
12.3 Resonance Health Limited
12.3.1 Overview
12.3.2 Resonance Health Limited: Recent Developments
12.4 Thermo Fisher Scientific
12.4.1 Overview
12.4.2 Thermo Fisher Scientific: Recent Developments
12.5 Genomic Health, Inc.
12.5.1 Overview
12.5.2 Genomic Health: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 REGULATORY SCENARIO
Table 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY VENDOR RANKING, 2017
Table 4 OTHER PROMINENT VENDORS OF COMPANION DIAGNOSTICS MARKET
Table 5 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 6 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 7 QIAGEN N.V.: PRODUCT OFFERINGS
Table 8 QIAGEN N.V.: RECENT DEVELOPMENTS
Table 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 11 MYRIAD GENETICS: PRODUCT DESCRIPTION
Table 12 MYRIAD GENETICS: RECENT DEVELOPMENTS
Table 13 AGILENT TECHNOLOGIES INC.: PRODUCT OFFERINGS
Table 14 AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
Table 15 BIOMERIEUX S.A.: SNAPSHOT
Table 16 DANAHER CORPORATION: SNAPSHOT
Table 17 RESONANCE HEALTH LIMITED: SNAPSHOT
Table 18 THERMO FISHER SCIENTIFIC: SNAPSHOT
Table 19 GENOMIC HEALTH: SNAPSHOT
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%)
Chart 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 9 GLOBAL COMPANION DIAGNOSTIC MARKET BY CANCER APPLICATION SEGMENTATION, 2017 (%)
Chart 10 GLOBAL COMPANION DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 12 COMPANION DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 13 COMPANION DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 14 COMPANION DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 15 COMPANION DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 20 QIAGEN N.V.: OVERVIEW SNAPSHOT
Chart 21 QIAGEN N.V.: GEOGRAPHICAL PRESENCE
Chart 22 QIAGEN N.V.: SWOT ANALYSIS
Chart 23 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT
Chart 24 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 25 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 26 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 27 MYRIAD GENETICS: OVERVIEW SNAPSHOT
Chart 28 MYRIAD GENETICS: BUSINESS UNITS
Chart 29 MYRIAD GENETICS: SWOT ANALYSIS
Chart 30 AGILENT TECHNOLOGIES INC.: OVERVIEW SNAPSHOT
Chart 31 AGILENT TECHNOLOGIES INC.: BUSINESS UNITS
Chart 32 AGILENT TECHNOLOGIES: GEOGRAPHICAL PRESENCE
Chart 33 AGILENT TECHNOLOGIES INC.: SWOT ANALYSIS
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Importance of Companion diagnostics
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the companion diagnostics market
3.5 Related Markets
3.5.1 Personalized medicine
3.5.2 Genetic testing Market
3.5.3 Point-Of-Care Diagnostics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Companion Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of cancer across the globe
5.1.1.2 Rising adoption of companion diagnostics tests
5.1.1.3 Growing demand of personalized medicine
5.1.2 Opportunities
5.1.2.1 Emerging applications of companion diagnostics
5.1.2.2 Growing demand for next-generation sequencing
5.1.3 Restraints
5.1.3.1 Uncertain reimbursement scenario in developed and developing countries
5.1.3.2 Lack of professionals to perform the test
6 TECHNOLOGY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Polymerase Chain Reaction
6.3 In Situ Hybridization
6.4 Immunohistochemistry
6.5 Next-Generation Sequencing
6.6 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Cancer
7.2.1 Lung cancer
7.2.2 Breast cancer
7.2.3 Colorectal cancer
7.2.4 Melanoma
7.2.5 Others
7.3 Infectious disease
7.4 Others
8 END USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Pharma and biopharma companies
8.3 Reference Laboratories
8.4 Others
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.2.2 US
9.2.3 Canada
9.3 Europe
9.3.1 Overview
9.3.2 UK
9.3.3 Germany
9.3.4 France
9.3.5 Spain
9.4 APAC
9.4.1 Overview
9.4.2 India
9.4.3 China
9.5 Rest of the World
10 COMPETITIVE LANDSCAPE
10.1 Overview
11 VENDOR PROFILES
11.1 F.Hoffmann-La Roche Ltd
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 Qiagen N.V.
11.2.1 Overview
11.2.2 Geographic Presence
11.2.3 Business Focus
11.2.4 SWOT Analysis
11.2.5 Business Strategies
11.3 Abbott Laboratories
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Myriad Genetics Inc.
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Business Focus
11.4.4 SWOT Analysis
11.4.5 Business Strategy
11.5 Agilent Technologies Inc.
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
12 COMPANIES TO WATCH FOR
12.1 BioMerieux S.A.
12.1.1 Overview
12.1.2 BioMerieux S.A.: Recent Developments
12.2 Danaher Corporation (Leica Microsystems AG)
12.2.1 Overview
12.2.2 Danaher Corporation: Recent Developments
12.3 Resonance Health Limited
12.3.1 Overview
12.3.2 Resonance Health Limited: Recent Developments
12.4 Thermo Fisher Scientific
12.4.1 Overview
12.4.2 Thermo Fisher Scientific: Recent Developments
12.5 Genomic Health, Inc.
12.5.1 Overview
12.5.2 Genomic Health: Recent Developments
13 ANNEXURE
13.1 Abbreviations
Tables
Table 1 REGULATORY SCENARIO
Table 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
Table 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY VENDOR RANKING, 2017
Table 4 OTHER PROMINENT VENDORS OF COMPANION DIAGNOSTICS MARKET
Table 5 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 6 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 7 QIAGEN N.V.: PRODUCT OFFERINGS
Table 8 QIAGEN N.V.: RECENT DEVELOPMENTS
Table 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS
Table 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 11 MYRIAD GENETICS: PRODUCT DESCRIPTION
Table 12 MYRIAD GENETICS: RECENT DEVELOPMENTS
Table 13 AGILENT TECHNOLOGIES INC.: PRODUCT OFFERINGS
Table 14 AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
Table 15 BIOMERIEUX S.A.: SNAPSHOT
Table 16 DANAHER CORPORATION: SNAPSHOT
Table 17 RESONANCE HEALTH LIMITED: SNAPSHOT
Table 18 THERMO FISHER SCIENTIFIC: SNAPSHOT
Table 19 GENOMIC HEALTH: SNAPSHOT
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%)
Chart 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 9 GLOBAL COMPANION DIAGNOSTIC MARKET BY CANCER APPLICATION SEGMENTATION, 2017 (%)
Chart 10 GLOBAL COMPANION DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%)
Chart 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 12 COMPANION DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION)
Chart 13 COMPANION DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION)
Chart 14 COMPANION DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024 ($MILLION)
Chart 15 COMPANION DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION)
Chart 20 QIAGEN N.V.: OVERVIEW SNAPSHOT
Chart 21 QIAGEN N.V.: GEOGRAPHICAL PRESENCE
Chart 22 QIAGEN N.V.: SWOT ANALYSIS
Chart 23 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT
Chart 24 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 25 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 26 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 27 MYRIAD GENETICS: OVERVIEW SNAPSHOT
Chart 28 MYRIAD GENETICS: BUSINESS UNITS
Chart 29 MYRIAD GENETICS: SWOT ANALYSIS
Chart 30 AGILENT TECHNOLOGIES INC.: OVERVIEW SNAPSHOT
Chart 31 AGILENT TECHNOLOGIES INC.: BUSINESS UNITS
Chart 32 AGILENT TECHNOLOGIES: GEOGRAPHICAL PRESENCE
Chart 33 AGILENT TECHNOLOGIES INC.: SWOT ANALYSIS
